Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.

Harry J. M. Groen; Wallace L. Akerley; Pierre Jean Souquet; Eckart Laack; Ji-Youn Han; Egbert F. Smit; Aaron Scott Mansfield; Edward B. Garon; Juergen Wolf; Daniel Shao-Weng Tan; Rebecca Suk Heist; Maeve Waldron-Lynch; Sylvie Le Mouhaer; Ngozi Nwana; Monica Giovannini; Sergey Orlov

Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.

Harry J. M. Groen, Wallace L. Akerley, Pierre Jean Souquet, Eckart Laack, Ji-Youn Han, Egbert F. Smit, Aaron Scott Mansfield, Edward B. Garon, Juergen Wolf, Daniel Shao-Weng Tan, Rebecca Suk Heist, Maeve Waldron-Lynch, Sylvie Le Mouhaer, Ngozi Nwana, Monica Giovannini, Sergey Orlov

Onderzoeksoutput › Academic

Originele taal-2	English
Aantal pagina's	2
Tijdschrift	Journal of Clinical Oncology
Volume	38
Nummer van het tijdschrift	15
Status	Published - 20-mei-2020

Handle.net

Permanente koppeling

Citeer dit

Groen, H. J. M., Akerley, W. L., Souquet, P. J., Laack, E., Han, J-Y., Smit, E. F., Mansfield, A. S., Garon, E. B., Wolf, J., Tan, D. S-W., Heist, R. S., Waldron-Lynch, M., Le Mouhaer, S., Nwana, N., Giovannini, M., & Orlov, S. (2020). Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study. Journal of Clinical Oncology, 38(15).

@article{dde86604bc5a4d8280086485965a8136,

title = "Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.",

author = "Groen, {Harry J. M.} and Akerley, {Wallace L.} and Souquet, {Pierre Jean} and Eckart Laack and Ji-Youn Han and Smit, {Egbert F.} and Mansfield, {Aaron Scott} and Garon, {Edward B.} and Juergen Wolf and Tan, {Daniel Shao-Weng} and Heist, {Rebecca Suk} and Maeve Waldron-Lynch and {Le Mouhaer}, Sylvie and Ngozi Nwana and Monica Giovannini and Sergey Orlov",

year = "2020",

month = may,

day = "20",

language = "English",

volume = "38",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "AMER SOC CLINICAL ONCOLOGY",

number = "15",

}

Groen, HJM, Akerley, WL, Souquet, PJ, Laack, E, Han, J-Y, Smit, EF, Mansfield, AS, Garon, EB, Wolf, J, Tan, DS-W, Heist, RS, Waldron-Lynch, M, Le Mouhaer, S, Nwana, N, Giovannini, M & Orlov, S 2020, 'Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.', Journal of Clinical Oncology, vol. 38, nr. 15.

TY - JOUR

T1 - Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non-small-cell lung cancer (NSCLC)

T2 - results from cohort 6 of the phase 2 GEOMETRY mono-1 study.

AU - Groen, Harry J. M.

AU - Akerley, Wallace L.

AU - Souquet, Pierre Jean

AU - Laack, Eckart

AU - Han, Ji-Youn

AU - Smit, Egbert F.

AU - Mansfield, Aaron Scott

AU - Garon, Edward B.

AU - Wolf, Juergen

AU - Tan, Daniel Shao-Weng

AU - Heist, Rebecca Suk

AU - Waldron-Lynch, Maeve

AU - Le Mouhaer, Sylvie

AU - Nwana, Ngozi

AU - Giovannini, Monica

AU - Orlov, Sergey

PY - 2020/5/20

Y1 - 2020/5/20

M3 - Meeting Abstract

VL - 38

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 15

ER -